News: Simtuzumab

We provide the latest news and info on Simtuzumab

Is Intercept Pharmaceuticals, Inc. Overvalued?
Motley Fool
Simtuzumab is a monoclonal antibody that targets LOXL2, an enzyme involved in the production of connective tissues, including the fibrous connective tissue formed in the liver in inflammatory diseases like NASH. Enrollment has been slow here, though ...

and more »

Published on Monday 14th of April 2014 02:46:22 AM Read more...


OncLive
Gilead Sciences Moves Ahead on Idelalisib Filings
OncLive
Rounding out the company's other oncology offerings are momelotinib, simtuzumab, GS-9973 (a Syk inhibit or), GS-9820 (a PI3K delta inhibitor), and GS-5745 (an MMP9 mAb inhibitor). Momelotinib, an investigational JAK inhibitor that has shown promise for ...

Published on Monday 14th of April 2014 02:46:22 AM Read more...

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney ...
News-Medical.net
A complementary approach to GFT505 and OCA is being developed by Gilead (Simtuzumab, GS-6624, currently in phase 2) and Galectin (GR-MD-02, currently in Phase 1), with the objective to directly attack bridging fibrosis and cirrhosis in patients with ...

Published on Monday 14th of April 2014 02:46:22 AM Read more...

What's Next for Geron and Imetelstat?
Motley Fool
In addition, Gilead has an in-house developed therapy, simtuzumab, also being studied in mid-stage trials as a potential myelofibrosis therapy. The point being that JAK2 inhibitors dominate the current landscape of myelofibrosis... with the exception ...

and more »

Published on Monday 14th of April 2014 02:46:22 AM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts